This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Tolerability of High-Dose Aripiprazole in Treatment-Refractory Schizophrenic Patients

Andrya M. Crossman, MD, and Jean-Pierre Lindenmayer, MD

Published: July 14, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Aripiprazole is a new antipsychotic that works as a partial agonist/antagonist at dopamine D2 and serotonin 5-HT1A receptors and has a favorable side effect profile.1 The maximum manufacturer-recommended dose in the United States is 30 mg/day, although patients with a history of antipsychotic nonresponse are likely to be treated with aripiprazole doses over 30 mg. Review of the literature found 1 safety study of 40 patients with stable schizophrenia or schizoaffective disorder who were administered aripiprazole 30 to 90 mg with no dose-dependent increases of adverse events.2‘ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 67

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...

Read More...